Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease

Urology

Volumn 47, Issue 2, 1996, Pages 236-239

  Zietman, Anthony L ^a,b   Dallow, Katherine C ^a   McManus, Patricia A ^a   Heney, Niall M ^a   Shipley, William U ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSIS; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; SURVIVAL TIME;

EID: 0029995206     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80423-3     Document Type: Article

References (13)

1. Zietman AL, and Shipley WU: Randomized trials in loco-regionally confined prostate cancer: past, present, and future. Semin Radiat Oncol 3: 210-220, 1993.
2. Pilepich MV, Krall JM, Johnson RJ, Sause WT, Perez CA, Zinninger M, and Martz K: Extended field (periaortic) irradiation in carcinoma of the prostate - analysis of RTOG 75-06. Int J Radiat Oncol Biol Phys 12: 345-351, 1986.
3. Pilepich MV, Krall JM, John MJ, Rubin P, Porter AT, Marcial VA, and Martz KL: Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: preliminary results of RTOG 83-07. Int J Radiat Oncol Biol Phys 16: 813-817, 1989.
4. Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ, et al: Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32: 3-12, 1995.
5. Fleming TR: Surrogate markers in AIDS and cancer trials. Stat Med 13: 1423-1435, 1994.
6. O'Shaughnessy JA, Wittes RE, Burke G, Friedman MA, Johnson JR, Niederhuber JE, Rothenberg ML, Woodcock J, Chabner BA, and Temple R: Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 9: 2225-2232, 1991.
7. Hanks GE, D'Amico A, Epstein BE, and Schultheiss TE: Prostate-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys 27: 125-127, 1993.
8. Lange PH: Prostate-specific antigen for staging prior to surgery and for early detection of recurrence after surgery. Urol Clin North Am 17: 813-817, 1990.
9. Anonymous: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Metaanalysis Project. J Clin Oncol 10: 896-903, 1992.
10. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Tormey DC, Glick JH, Veeder MH, and Mailliard JA: Levamisole and fluorouracil for adjuvant therapy of stage III colon carcinoma: a final report. J Clin Oncol (in press).
11. Crawford ED, and Nabors WL: Total androgen ablation: American experience. Urol Clin North Am 18: 55-63, 1991.
12. Denis L, Smith P, Carneiro de Moura JL, Newling D, Bono A, Keuppens F, Mahler C, Robinson M, Sylvester R, De Pauw M, et al: Total androgen ablation: European experience. Urol Clin North Am 18: 65-73, 1991.
13. 2 prostate cancer. Interim evaluation of Intergroup study 0105 (abstract 613). Proc Am Soc Clin Oncol 14: 235, 1995.